Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

BioEscalator Mini Supplier Show. Laboratory Equipment and Services. BioEscalator/University of Oxford logo. Olink logo. Analytik-Jena logo. Stemcell logo. Tecan logo. Image of a microscope.

The BioEscalator holds its first mini supplier show

The show hosted four laboratory equipment and services companies: Olink, Stemcell, Analytik-Jena UK, and Tecan.

A group of people eating lunch and socialising in the park

Fun in the sun at BioEscalator's Party in the Park

The BioEscalator team and resident companies made their way to South Park, Oxford, today to enjoy well-deserved downtime at the BioEscalator's first Party in the Park.

Theraport logo

Introducing Theraport

Winner of OUBT's Biohackathon 2022, part of the Oxford Catalyse Programme, Theraport join the BioEscalator community for three months.

Oxford Cancer Analytics logo

Introducing Oxford Cancer Analytics

OXcan, short for Oxford Cancer Analytics, uses machine learning techniques combined with cutting-edge liquid biopsy techniques, to search for stage one lung cancer biomarkers.

Evolvere Biosciences logo

Introducing Evolvere Biosciences

A platform to develop biologic therapeutics that outsmart the evolution of antibiotic resistance to save millions of lives.

Images of the exterior of the BioEscalator building, a BioEscalator innovation laboratory, and a female scientist using a fume hood in the BioEscalator shared core laboratory facilities.

Tours and tenant talks at the BioEscalator open afternoon

The event's purpose was to raise awareness of the BioEscalator and showcase the incredible science happening within its walls.

A stack of packed moving boxes with a plant on the top. Cyanocapture logo.

CyanoCapture moves on from the BioEscalator

The company has moved into the newly refurbished Hayakawa Building at the Oxford Science Park.

A liver with a heartbeat monitor line running through it.

Ochre Bio has announced the launch of its ‘Liver ICU’ in the US to Evaluate Effects of RNA Therapies on Human Liver Performance

This research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.

Oxfordshire Business Awards logo. Nucleome Therapeutics logo. The Oxfordshire LEP New Business Award Finalist.

Nucleome Therapeutics shortlisted as a finalist for the 2022 Oxfordshire Business Awards

Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.

A cluster of hexagons. The hexagon in the centre has IPO written in the centre. The other hexagons have graphics in the centre of them including a group of people connected by lines, a graph, a stack of money, a DNA strand, and a pencil writing on a document.

PepGen Announces Pricing of Initial Public Offering

The shares are expected to begin trading on the Nasdaq Global Select Market on 6 May 2022 under the symbol “PEPG.” The offering is expected to close on 10 May 2022, subject to the satisfaction of customary closing conditions.

Different currency symbols (dollar, pounds, yen, euro) in the middle hexagon shapes are connected by lines to create a geometric look.

Exogene Raises $2M (£1.5M) for Its AI Platform to Discover Cell Therapies for Cancer

Exogene, a biotech company discovering novel T-cell receptor-based cell therapies, has raised $2M in funding to develop its artificial intelligence (AI) platform for T-cell receptor discovery.

Futuristic graphic of a body with the cardiovascular system highlighted. Kyttaro logo. Lilly logo.

Kyttaro enters Worldwide Exclusive Licensing Agreement with Eli Lilly for Antibody Therapeutic Programme

The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.

Syringe taking a dose from a bottle

PepGen announced its first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy

Initiation of Phase 1 Study marks PepGen’s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.

An image of a lightbulb with money (notes) flying around it.

Oxford Silk Phage Technologies awarded three consecutive grants from OxLEP’s ISfB programme

OSPT has been awarded £680K to advance its disruptive antibacterial technology.

OUBT logo, BioEscalator logo, Arctoris logo & Oxford Nanopore Technologies

BioEscalator sponsors Oxford Catalyse Programme 2022

The BioEscalator is sponsoring a prize for the Biohackaton 2022, where teams created during the Oxford Catalyse 2022 programme will pitch their final business plans to a panel of judges.

A photo of the BioEscalator's new laboratory space. Rows of bench space with a glass panel wall reflecting the outside behind them.

BioEscalator opens new laboratory

In December 2021, the BioEscalator opened a brand-new 137m2 laboratory, providing much-needed additional incubator space for Oxford-based start-ups.

Alethiomics logo

Introducing Alethiomics

Alethiomics Ltd is a pre-clinical biotech company harnessing the power of single cell multiomic technology to discover and develop life-changing treatments for patients with blood cancer.

A team hand stack (people's hands placed on top of each other) to the left with the Bioarchitech and SIGA Human Bioarmor logos to the right.

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

The research collaboration will investigate TPOXX® (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform in preclinical studies.

Kyttaro and OUI logos, each in a jigsaw piece, slotting together.

Kyttaro Announces an Exclusive Worldwide Licensing Agreement with Oxford University Innovation

Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.

Two hands hold a liver in the middle of the image. The Ochre Bio logo is on the top right of the image. The British Liver Trust logo is on the bottom left of the image.

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

The two companies share the same goals, to improve the lives of those dealing with liver disease.